--- title: "Analytical Innovation in Biologics Development: Making Better Decisions Earlier" canonical: "/analytical-innovation-in-biologics-development-making-better-decisions-earlier-" published: 2026-09-21 --- # Analytical Innovation in Biologics Development: Making Better Decisions Earlier [https://nanotempertech.com/](https://nanotempertech.com/) Solutions Choose Solutions Application Products Consumables Application Products Consumables Biologics [Be confident you’re choosing the right biologics candidates.](/biologics/) Products [Prometheus](https://nanotempertech.com/prometheus-panta/) [Learn more](/biologics/) Targeted Protein Degradation [Advance your TPD and induced proximity research.](/tpd/) Products [Dianthus](https://nanotempertech.com/dianthus/) [Dianthus uHTS](https://nanotempertech.com/dianthus-uhts/) [Learn more](/tpd/) Membrane Proteins [Characterize membrane proteins in complex environments with confidence.](/membrane-protein/) Products [Monolith](https://nanotempertech.com/monolith/) [Prometheus](https://nanotempertech.com/prometheus-panta/) [Learn more](/membrane-protein/) [Protein Stability Prometheus Panta One experiment. Multiple insights.](/prometheus-panta/) [Affinity screening Dianthus Tough targets. Confident decisions.](/dianthus/) [High-throughput screening Dianthus uHTS Screen faster. Discover more.](/dianthus-uhts/) [Affinity measurement Monolith Minimal sample. Maximum insight.](/monolith/) [Protein stability Andromeda Crude lysates. Early decisions.](/andromeda/) [Consumables Capillaries and plates designed for high reproducibility. Go to shop](https://shop.nanotempertech.com/) [Reagents Labeling kits and reagents for straightforward assay set up. Go to shop](https://shop.nanotempertech.com/)Technologies [nanoDSF](https://nanotempertech.com/nanodsf/)[Dynamic Light Scattering (DLS)](https://nanotempertech.com/dls-7/)[Static Light Scattering (SLS)](https://nanotempertech.com/sls-6/)[Backreflection](https://nanotempertech.com/backreflection/)[Spectral Shift](https://nanotempertech.com/spectral-shift/)[MicroScale Thermophoresis (MST)](https://nanotempertech.com/mst/)[Temperature Related Intensity Change (TRIC)](https://nanotempertech.com/tric/)[Resources](https://nanotempertech.com/resources/)[Support](https://nanotempertech.com/support/)[About](https://nanotempertech.com/about/)[Shop](https://shop.nanotempertech.com/) EN English汉语 EN English汉语 Search Search{results\_count} resultsDisplaying **{results\_count}** results of **{results\_count\_total}**[More results...](https://nanotempertech.com) ## Analytical innovation in biologics development: Why better decisions start earlier. ###### In biologics development, speed matters. But speed without confidence is just risk in disguise. That was one of the clearest messages from our recent panel discussion on “Analytical innovation as a strategic driver of quality, speed, and success in biologics development” held during the last NextGen Biomed conference in London this March. **last NextGen Biomed conference** Moderated by Ping Zhang, Product Manager at NanoTemper, the panel brought together leaders working across discovery, CMC (Chemistry, Manufacturing ,and Controls), and analytical development: - Beth Wesley, Principal Scientist, LifeArc, leading protein and analytical sciences in discovery - Agnieszka Lewandowska, Associate Director, Immunocore,focused on analytical development and bioassays across clinical stages - Salis Rabelo, Associate Director, AstraZeneca, specializing in physicochemical and biophysical characterization of biologics across development stages The conversation pointed to a meaningful shift: analytical strategies are no longer being treated as downstream support functions. They are becoming central to how teams make better decisions earlier in development. ### The key takeaway: analytical innovation is only valuable when it is intentional. ###### The strongest thought running through the discussion was this: more data is not the same as better insight. Teams are moving away from simply adding more assays and more complexity. Instead, they are asking a more strategic question: What does this method need to answer, at this stage, to move the program forward with confidence? That phase-appropriate mindset, grounded in frameworks like Quality Target Product Profile (QTPP), Quality by Design (QbD), and Analytical Quality by Design (AQbD), is helping organizations make smarter analytical decisions from preclinical development through commercialization. ### High-throughput, automation, and AI are changing expectations. Another clear theme was that high-throughput technologies and automation are enabling earlier, more informed candidate evaluation. As biologics pipelines become more complex, teams need tools and workflows that can keep pace without compromising data quality. AI also featured prominently in the discussion, but with an important caveat: its value depends entirely on the quality and consistency of the underlying data. The panel emphasized that successful AI in biologics development will likely come not from hype-driven adoption, but from targeted, practical applications built on strong experimental foundations. ### Quality analytics must be embedded, not added later. Perhaps the most important leadership message is that quality analytics should not be viewed as a late-stage checkpoint. It needs to be embedded across the development continuum, informing decisions in upstream and downstream processing, formulation, and release strategy alike. For teams working on novel or complex modalities, this means identifying analytical and CMC challenges early, engaging cross-functional stakeholders sooner, and building data integrity into the process from the start. ### Looking ahead. The future of biologics development will be shaped by organizations that treat analytical innovation as a strategic capability, not a technical afterthought. The combination of AQbD, automation, high-throughput methods, and fit-for-purpose AI is creating a new model for development: one that is faster, more connected, and more resilient. For us at NanoTemper, this reflects a broader truth: analytical innovation creates the most value when it helps scientists and biopharma teams move from data to decision faster and with greater confidence. ##### There's more to explore ###### Discover more science-led content, practical guidance, and resources to deepen your knowledge and move your research forward with confidence. **Back to resource centre** Breakthrough faster. Together. [Let's talk](https://nanotempertech.com/contact-specialist/) newsletter Get our latest publications, webinars, and case studies. [https://nanotempertech.com/](https://nanotempertech.com/) We develop biophysical tools and reagents for discovery, development, and beyond. Helping teams to breakthrough faster, together. Explore Explore [Resources](https://nanotempertech.com/resources/) [About](https://nanotempertech.com/about/) [Careers](https://nanotempertech.com/careers/) [Contact](https://nanotempertech.com/contact-specialist/) Solutions [Biologics](https://nanotempertech.com/biologics/) [TPD](https://nanotempertech.com/tpd/) [Membrane Protein](https://nanotempertech.com/membrane-protein/) [Products](https://nanotempertech.com/#solutions) [Consumables](https://shop.nanotempertech.com/) [Support](https://nanotempertech.com/support/) Technologies [nanoDSF](https://nanotempertech.com/nanodsf/) [DLS](https://nanotempertech.com/dls-7/) [SLS](https://nanotempertech.com/sls-6/) [Backreflection](https://nanotempertech.com/backreflection/) [Spectral Shift](https://nanotempertech.com/spectral-shift/) [MST](https://nanotempertech.com/mst/) [TRIC](https://nanotempertech.com/tric/) [LinkedIn](https://www.linkedin.com/company/nanotemper-technologies-gmbh) [YouTube](https://www.youtube.com/user/NanoTemper) © 2026 NanoTemper Technologies. All Rights Reserved. [Imprint](https://nanotempertech.com/imprint/) [Privacy Policy](https://nanotempertech.com/privacy-policy/)